Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07715084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Azafaros B.V.
6 trials monitored
See 3 trials at risk
A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).
Trial Details
NCT Number NCT07715084
Lead Sponsor Azafaros B.V.
Conditions
(from sponsor)		 Gaucher Disease Type 3
Related terms Gaucher Disease
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov